Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.
Novo Nordisk (0QIU) Gets a Buy from J.P. Morgan
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
24/7 Wall St6d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
thecutoffnews11d
Medicaid Now Covers GLP-1s for Obesity in Alabama
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Hastings Tribune11d
Kansas Medicaid Spend on GLP-1s for Obesity up 97% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
WFMZ-TV11d
Pennsylvania Medicaid Spent $297.8M on GLP-1s for Obesity Over the Past 12 Months
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ... GLP-1s—including the District of Columbia, Florida, and New Jersey—also ...
Benefits Pro14d
Employers take fights with Big Pharma and PBMs over insulin price-gouging charges to one federal court
A lawyer for the employers predicts that discovery will show that collusion between drugmakers and PBMs had a significant ...